Brind.

Gilead Sciences and T. Rowe Price are currently among the largest dividend payers.

1 report, 1 independent Updated Sep 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences T. Rowe Price

Keep exploring

The entities involved

Gilead Sciences
American company
- FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.Mon 18:04
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
T. Rowe Price
American publicly owned investment firm
- Voya Financial and T. Rowe Price are identified as operating within the asset management segment.Sun 05:38
- T. Rowe Price recommends that retirees hold cash in response to current market conditions.Thu 20:43

Coverage

Newest first; wire copies grouped

Sep 15247wallst.com